Benzinga
España
Italia
대한민국
日本
Français
My Account
Login
SPY
772.17
0.47%
QQQ
720.96
0.88%
BTC/USD
64802.68
0.8461%
DIA
539.00
0.15%
GLD
398.07
2.16%
TLT
82.56
0.05%
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
Italia
대한민국
日本
Français
Login
Register
Benzinga
Premium Services
Benzinga Edge
Benzinga Pro
Benzinga Research
Benzinga APIs
Financial News
Financial News
Large Cap Stocks
Small-Cap Stocks
Insider Trades
Earnings
Technology
AI News
Personal Finance
ETF News
Crypto News
Dividend News
Latest Rumors
Latest Offerings News
Investment Ideas
Investment Ideas
Stock of the Day
Stock Whisper Index
Analyst Ratings
Analyst Color
Financial Advisors
Government Trades
Trading Ideas
Stock Screener
Markets
Markets
Premarket Movers
After Hours
Options
ETFs
Commodities
Prediction Markets
Private Markets
Bonds
Futures
Forex
Top Stocks
Top Stocks
Apple (AAPL)
Tesla (TSLA)
Amazon (AMZN)
Nvidia (NVDA)
Alphabet (GOOGL)
Meta Platforms (META)
Microsoft (MSFT)
StreetTracks Gold Shares (GLD)
IBIT Bitcoin Trust (IBIT)
Top Value Stocks
Top Momentum Stocks
Top Growth Stocks
Top Quality Stocks
Learn
Learn
Investing Guides
Personal Finance
Mortgages
Best Credit Cards
Best Dividend Stocks
Best Swing Trade Stocks
Investment Ideas
Investment Ideas
Stock of the Day
Stock Whisper Index
Analyst Ratings
Analyst Color
Financial Advisors
Government Trades
Trading Ideas
Stock Screener
Markets
Markets
Premarket Movers
After Hours
Options
ETFs
Commodities
Prediction Markets
Private Markets
Bonds
Futures
Forex
Top Stocks
Top Stocks
Apple (AAPL)
Tesla (TSLA)
Amazon (AMZN)
Nvidia (NVDA)
Alphabet (GOOGL)
Meta Platforms (META)
Microsoft (MSFT)
StreetTracks Gold Shares (GLD)
IBIT Bitcoin Trust (IBIT)
Top Value Stocks
Top Momentum Stocks
Top Growth Stocks
Top Quality Stocks
Learn
Learn
Investing Guides
Personal Finance
Mortgages
Best Credit Cards
Best Dividend Stocks
Best Swing Trade Stocks
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
Events Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Options Profit Calculator
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Covered Call Calculator
Cash-Secured Put Calculator
Long Call Calculator
Long Put Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Markets
SPY
772.17
0.47%
QQQ
720.96
0.88%
BTC/USD
64802.68
0.8461%
DIA
539.00
0.15%
GLD
398.07
2.16%
TLT
82.56
0.05%
Jazz Pharmaceuticals PLC
JAZZ
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$257.79
1.14
0.44%
Last update: Aug 7, 2:04 PM
Get Report
Earnings:
Q2 2026 Earnings were released on Mon Aug 3rd, after the market close
Conference Call:
The most recent conference call started at 4:30 PM, 4 days ago
Click to view the webcast
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Compare
Options
Stock Report
Jazz Pharmaceuticals Financials
Jazz Pharmaceuticals (JAZZ) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results
Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. Analysts have mixed opinions, with some raising price targets. Consider buying JAZZ stock.
Avi Kapoor
PRO
Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.250B-$4.500B to $4.600B-$4.750B vs $4.517B Est
Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.600 billion-$4.750 billion vs $4.517 billion estimate.
Benzinga Newsdesk
PRO
Jazz Pharmaceuticals Q2 Adj. EPS $5.71 Misses $6.18 Estimate, Sales $1.208B Beat $1.115B Estimate
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $5.71 per share which missed the analyst consensus estimate of $6.18 by 7.61 percent. This is a 169.21 percent increase over losses of $(8.25) per share
Benzinga Newsdesk
PRO
Jazz Pharmaceuticals Affirms FY2026 Sales Guidance of $4.250B-$4.500B vs $4.445B Est
Jazz Pharmaceuticals (NASDAQ:JAZZ) affirms FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.250 billion-$4.500 billion vs $4.445 billion estimate.
Benzinga Newsdesk
PRO
Jazz Pharmaceuticals Q1 Adj. EPS $6.34 Beats $4.57 Estimate, Sales $1.609B Beat $976.563M Estimate
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $6.34 per share which beat the analyst consensus estimate of $4.57 by 38.73 percent. This is a 277.38 percent increase over earnings of $1.68 per share
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights